Dec 17, 2014 by Brian Orelli, PhDBetter Big Pharma Spinoff: Zoetis Inc. or AbbVie Inc.?Both AbbVie and Zoetis offer something for healthcare investors.
Dec 16, 2014 by Brian Orelli, PhDTwitter's Favorite Biotech and Pharma StocksConsensus? We don't need no stinking consensus!
Dec 13, 2014 by Brian Orelli, PhDCan These Top Dividend-Paying Stocks Soar in 2015?There's more to top dividend-paying stocks than the yield.
Dec 12, 2014 by Brian Orelli, PhDIs MannKind Corporation in Bed With Crooks? And Should Investors Care?MannKind's marketing partner, Sanofi, may be in big trouble.
Dec 5, 2014 by Brian Orelli, PhDGilead Sciences, Inc. Beats Another ThreatA U.K. court knocks down Idenix Pharmaeuticals' rights to Gilead Sciences' Sovaldi.
Dec 4, 2014 by Brian Orelli, PhDDendreon's Alternate RealityWhat if everything went perfectly right for the biotech?
Nov 29, 2014 by Brian Orelli, PhDBristol-Myers Squibb Co's Hep C Drug Denied; Gilead Sciences Inc. Smiling (for Now)The FDA rejected daclatasvir, but Bristol-Myers Squibb still has plans for the hepatitis C drug.
Nov 26, 2014 by Brian Orelli, PhDWill Insulin Pricing Be MannKind Corporation's Downfall?MannKind marketing partner Sanofi had to discount its Lantus insulin to get insurers to cover the drug.
Nov 24, 2014 by Brian Orelli, PhDGilead Sciences Inc. Just Paid $125 Million for Something It Can't Use for a YearGilead's newly acquired priority review voucher is useful, but requires the biotech to give the FDA a 365-day warning that it's going to use the voucher.
Nov 18, 2014 by Brian Orelli, PhDMerck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve TooThanks to Merck, Regeneron Pharmaceuticals and Esperion Therapeutics likely won't have to run outcomes studies on their cholesterol drugs.
Nov 17, 2014 by Brian Orelli, PhDFor This Obesity Drug, Europe Trumps the U.S.Europe is key for Orexigen's Contrave. Shares jumped despite problems with the U.S. launch.
Nov 11, 2014 by Brian Orelli, PhDGilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So MuchMerck's new hepatitis C combination doesn't work all that well for short durations. Gilead Sciences' Harvoni is safe for now.
Nov 7, 2014 by Brian Orelli, PhDIsis Pharmaceuticals Inc. Strikes Out on Its OwnIsis Pharmaceuticals uses its third-quarter earnings call to announce a reorganization as it pushes into late-stage development on its own.
Nov 7, 2014 by Brian Orelli, PhD5 Things Biogen Idec Inc's Management Wants You to KnowBiogen Idec's multiple sclerosis and hemophilia pipelines are progressing.
Nov 6, 2014 by Brian Orelli, PhDEmergent BioSolutions Inc Busts Through Guidance. Sort of.Emergent BioSolutions' upfront payment from its deal with MorphoSys caused a large increase in revenue in the third quarter.
Nov 6, 2014 by Brian Orelli, PhDAll Eyes on ISIS Pharmaceuticals, Inc.'s PipelineIsis has an approved drug, but earnings should be all about the pipeline of 32 drugs.
Nov 5, 2014 by Brian Orelli, PhDAlnylam Pharmaceuticals, Inc. Has This Ratio RightAlnylam's third-quarter earnings call was all about the pipeline data.
Nov 5, 2014 by Brian Orelli, PhDMomenta Pharmaceuticals, Inc. Pushes ForwardWith just $4.7 million from sales of enoxaparin in the third quarter, investors have to be focused on the pipeline.
Nov 5, 2014 by Brian Orelli, PhDGenomic Health, Inc.'s Lumpy Growth Revenue and test volume growth come back to earth, but investors should focus on the quarters ahead.
Nov 4, 2014 by Brian Orelli, PhDRegeneron Pharmaceuticals Inc. Earnings: Eylea's Roller-Coaster RideRegeneron Pharmaceuticals guides for 2014 U.S. Eylea sales toward the low end of previous guidance, causing shares to slip.
